Clinical Trials Logo

Clinical Trial Summary

The present study will establish a collection of biological samples from Noonan patients to be used for research purposes only, with due respect for confidentiality.


Clinical Trial Description

Noonan syndrome is a rare autosomal dominant genetic disorder characterized by a combination of typical facial features, heart defects, short stature, skeletal abnormalities, mild developmental delay and a predisposition to myeloproliferative disorders. This syndrome is caused by germline mutations in genes encoding components or regulators of the Rat Sarcoma (RAS) / extracellular signal-regulated kinase (ERK) signaling pathway, which is essential for cell cycle differentiation, growth, and senescence. Patients with Noonan syndrome or related diseases are followed at the children's hospital, Toulouse University Hospital. During regular check-up visits, an extra sample of blood and urine will be collected and stored for research utilisation with the patient's consent. The ultimate objective of this collection is to provide available biological resources to facilitate the development of subsequent studies aimed at better characterizing the multisystemic disorders in Noonan syndrome, to understand the pathophysiology of the disease, and to identify biological factors that predict the severity and progression of the disease. The possibility of having systematically collected biological resources will make it possible to answer certain questions more quickly depending on the progress of research. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05202210
Study type Observational
Source University Hospital, Toulouse
Contact Thomas Edouard, MD, PhD
Phone 5 34 55 85 55
Email [email protected]
Status Recruiting
Phase
Start date January 26, 2022
Completion date January 26, 2032

See also
  Status Clinical Trial Phase
Completed NCT01529944 - Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658 Phase 3
Recruiting NCT05361811 - Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial N/A
Completed NCT00452725 - Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome Phase 3
Recruiting NCT04463316 - GROWing Up With Rare GENEtic Syndromes
Enrolling by invitation NCT05308927 - French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome
Recruiting NCT04395495 - RASopathy Biorepository
Completed NCT01529840 - Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome Phase 3
Recruiting NCT02713945 - Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome Phase 3
Completed NCT03435627 - Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)
Completed NCT02486731 - Hormonal Sensitivity in Patients With Noonan and LEOPARD Syndromes
Completed NCT01927861 - Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome Phase 3
Recruiting NCT04888936 - Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies
Completed NCT00960128 - Observational Prospective Study on Patients Treated With Norditropin® N/A
Terminated NCT00351221 - Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome Phase 2